Barclays Lifts Tenet Healthcare Corporation (THC) PT $229, Maintains Overweight Rating

Tenet Healthcare Corporation (NYSE:THC) is one of the most undervalued stocks to buy and hold for 5 years. On September 18, Barclays raised the firm’s price target on Tenet Healthcare to $229 from $208, while keeping an Overweight rating on the shares. The firm provided this sentiment as it incorporated updated price targets across the healthcare facilities and managed care group.

Earlier for Q2 2025, Tenet Healthcare reported a revenue of $5.27 billion, which was a 3.29% year-over-year improvement attributed to attractive same-store revenue growth, operational improvements, higher patient acuity, favorable payer mix, and expense management. The Ambulatory Care segment, which includes United Surgical Partners International/USPI, was a major driver of growth, reporting $498 million in Adjusted EBITDA, which showed an 11.4% increase.

This growth was fueled by a strong 7.7% increase in same-facility system-wide net patient service revenues and an 8.3% rise in net revenue per case, primarily due to favorable case mix and a focus on higher acuity volumes. The Hospital Operations and Services segment also saw strong growth, with Adjusted EBITDA of $623 million compared to $498 million in the prior year, benefiting from a 5.2% increase in net patient service revenue per adjusted admission.

Tenet Healthcare Corporation (NYSE:THC) is a diversified healthcare services company in the US that operates through two segments: Hospital Operations & Services and Ambulatory Care.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.